MLN2238, a proteasome inhibitor, induces caspase-dependent cell death, cell cycle arrest, and potentiates the cytotoxic activity of chemotherapy agents in rituximab-chemotherapy-sensitive or rituximab-chemotherapy-resistant B-cell lymphoma preclinical models
| Autor: | Gu, Juan J., Hernandez-Ilizaliturri, Francisco J., Mavis, Cory, Czuczman, Natalie M., Deeb, George, Gibbs, John, Skitzki, Joseph J., Patil, Ritesh, Czuczman, Myron S. |
|---|---|
| Zdroj: | Anti-Cancer Drugs; Nov2013, Vol. 24 Issue 10, p1030-1038, 9p |
| Databáze: | Complementary Index |
| Externí odkaz: |
|